Literature DB >> 14679489

Lower airway obstruction, bronchial hyperresponsiveness, and primary pulmonary hypertension in children.

Deepa Rastogi1, Pakkay Ngai, Robyn J Barst, Anastassios C Koumbourlis.   

Abstract

We investigated the prevalence and reversibility of lower airway obstruction (LAO) and its correlation with pulmonary artery pressure in children with primary pulmonary hypertension (PPH). The analysis was performed retrospectively in a cohort of children with PPH between 5-18 years of age. PPH was defined as mean pulmonary artery pressure (PAPm) >25 mmHg at rest, or >30 mmHg during exercise, with normal pulmonary capillary wedge pressure in the absence of other causes. Lower airway function was assessed by spirometry and maximal expiratory flow-volume curves. Lung volumes were measured by body plethysmography. Patients were assigned according to their pattern of lung function into "normal," "obstructive," and "restrictive" groups. The reversibility of LAO was defined as an increase of > or = 15% from baseline in forced expiratory volume at 1 sec (FEV1) and/or > or =20% in forced expiratory flow at 25-75% of forced vital capacity (FEF25-75%) in response to nebulized albuterol. An "obstructive" pattern was found in 23 children (59%), a "restrictive" pattern in 2 children (5%), and a "normal" pattern in 14 children (36%). Response to bronchodilator was documented in 78% of children with an "obstructive" pattern and in 22% of those with a "normal" pattern. The PAPm showed a significant positive correlation with the TLC, RV, and RV/TLC, but a negative one with the ratio FEV1/FVC. Our findings suggest that reversible LAO is the most common lung function abnormality among pediatric patients with PPH. Whether airway reactivity is a cause of or the result of PPH remains to be determined. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14679489     DOI: 10.1002/ppul.10363

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  8 in total

1.  Non-congenital heart disease associated pediatric pulmonary arterial hypertension.

Authors:  D D Ivy; J A Feinstein; T Humpl; E B Rosenzweig
Journal:  Prog Pediatr Cardiol       Date:  2009-12-01

Review 2.  Pulmonary Limitations in Heart Failure.

Authors:  Ivan Cundrle; Lyle J Olson; Bruce D Johnson
Journal:  Clin Chest Med       Date:  2019-06       Impact factor: 2.878

3.  Effect of cardiac resynchronization therapy on pulmonary function in patients with heart failure.

Authors:  Ivan Cundrle; Bruce D Johnson; Virend K Somers; Christopher G Scott; Robert F Rea; Lyle J Olson
Journal:  Am J Cardiol       Date:  2013-06-05       Impact factor: 2.778

4.  Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.

Authors:  D Dunbar Ivy; Aimee K Doran; Kelly J Smith; George B Mallory; Maurice Beghetti; Robyn J Barst; Daniela Brady; Yuk Law; Donna Parker; Lori Claussen; Steven H Abman
Journal:  J Am Coll Cardiol       Date:  2008-01-15       Impact factor: 24.094

5.  Imitators of exercise-induced bronchoconstriction.

Authors:  Pnina Weiss; Kenneth W Rundell
Journal:  Allergy Asthma Clin Immunol       Date:  2009-11-17       Impact factor: 3.406

Review 6.  Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders.

Authors:  Claudia R Morris; Mark T Gladwin; Gregory J Kato
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

7.  Modification of hemodynamic and immune responses to exposure with a weak antigen by the expression of a hypomorphic BMPR2 gene.

Authors:  Sung-Hyun Park; Wen-Chi Chen; Carol Hoffman; Leigh M Marsh; James West; Gabriele Grunig
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

8.  Loss of alveolar membrane diffusing capacity and pulmonary capillary blood volume in pulmonary arterial hypertension.

Authors:  Samar Farha; Daniel Laskowski; Deepa George; Margaret M Park; W H Wilson Tang; Raed A Dweik; Serpil C Erzurum
Journal:  Respir Res       Date:  2013-01-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.